- •DeepSeek V4 Flash argues HOLD because The short thesis remains intact: ABBV has declined from $255.18 to $246.43 (-3.4%) and today's +0.67% bounce is a normal pullback within a downtrend, not a reversal. Price is testing 4h resistance at $247.56 with depressed volume and negative MACD structure — conditions that favor rejection and resumption toward the $240 target. With 56.9% progress remaining, 6 days left in the horizon, and a well-defined effective stop at $251.77, the risk/reward still favors holding for the remaining downside.
- •What changed: ABBV reached ex-dividend date today (triggering this reanalysis). The stock bounced +0.67% from recent lows, which is a normal countertrend move within the 7-day decline. Peak progress was 78.2% but has retraced to 56.9% as the bounce developed. No structural invalidation has occurred — price remains below all key short-term resistance levels.
The short thesis remains intact: ABBV has declined from $255.18 to $246.43 (-3.4%) and today's +0.67% bounce is a normal pullback within a downtrend, not a reversal. Price is testing 4h resistance at $247.56 with depressed volume and negative MACD structure — conditions that favor rejection and resumption toward the $240 target. With 56.9% progress remaining, 6 days left in the horizon, and a well-defined effective stop at $251.77, the risk/reward still favors holding for the remaining downside.
The original short thesis for ABBV remains intact. The stock is trading below key resistance at $247.56 and above support at $243.19, with improving bearish momentum on the 4h timeframe. The ex-dividend date has passed, which historically creates short-term pressure, and the sector/rates environment is confirming the move. The position is 56.9% toward the $240 target, with no signs of invalidation.
The short is at 56.9% progress (peaked 78.2%), price trades below 4h SMA20 and POC with negative 4h/1day MACD and 7 straight daily declines, and today's ex-dividend markdown plus Apogee/IPR&D EPS dilution reinforce the downside thesis. Target $240 is only ~2.7% away with the effective stop tightened to $251.77, preserving a favorable asymmetric R/R with the thesis path intact.
No model argued for EXIT.
- →Price breaks above 4h resistance at $247.56 with conviction, reclaims SMA20 at $250.96, and triggers the effective stop at $251.77, invalidating the short thesis as the ex-dividend pressure fades without follow-through.
Individual Model Review
The short is at 56.9% progress (peaked 78.2%), price trades below 4h SMA20 and POC with negative 4h/1day MACD and 7 straight daily declines, and today's ex-dividend markdown plus Apogee/IPR&D EPS dilution reinforce the downside thesis. Target $240 is only ~2.7% away with the effective stop tightened to $251.77, preserving a favorable asymmetric R/R with the thesis path intact.
The short is at 56.9% progress (peaked 78.2%), price trades below 4h SMA20 and POC with negative 4h/1day MACD and 7 straight daily declines, and today's ex-dividend markdown plus Apogee/IPR&D EPS dilution reinforce the downside thesis. Target $240 is only ~2.7% away with the effective stop tightened to $251.77, preserving a favorable asymmetric R/R with the thesis path intact.
▼ Click to expandA confirmed-bullish equity regime, dollar weakness, and fresh analyst upgrades (BMO $300, RBC) create upside risk, and today's +0.67% green session with rising 4h RSI could mark a bounce off 1day support $237.93 area toward resistance $247.56. If price reclaims SMA20 $250.96 and POC $252.43, the downtrend stalls and the short's edge erodes toward the effective stop.
▼ Click to expandThe short thesis remains intact: ABBV has declined from $255.18 to $246.43 (-3.4%) and today's +0.67% bounce is a normal pullback within a downtrend, not a reversal. Price is testing 4h resistance at $247.56 with depressed volume and negative MACD structure — conditions that favor rejection and resumption toward the $240 target. With 56.9% progress remaining, 6 days left in the horizon, and a well-defined effective stop at $251.77, the risk/reward still favors holding for the remaining downside.
The short thesis remains intact: ABBV has declined from $255.18 to $246.43 (-3.4%) and today's +0.67% bounce is a normal pullback within a downtrend, not a reversal. Price is testing 4h resistance at $247.56 with depressed volume and negative MACD structure — conditions that favor rejection and resumption toward the $240 target. With 56.9% progress remaining, 6 days left in the horizon, and a well-defined effective stop at $251.77, the risk/reward still favors holding for the remaining downside.
▼ Click to expandThe bounce today could extend if the ex-dividend pressure fades and the Fed testimony provides a risk-on catalyst that lifts healthcare stocks. Price has already given back some progress from the 78.2% peak, and the 4h RSI is rising from oversold levels, suggesting the countertrend bounce may have more room. If ABBV reclaims $247.56 with volume, the short thesis weakens and the effective stop at $251.77 becomes vulnerable.
▼ Click to expandThe original short thesis for ABBV remains intact. The stock is trading below key resistance at $247.56 and above support at $243.19, with improving bearish momentum on the 4h timeframe. The ex-dividend date has passed, which historically creates short-term pressure, and the sector/rates environment is confirming the move. The position is 56.9% toward the $240 target, with no signs of invalidation.
The original short thesis for ABBV remains intact. The stock is trading below key resistance at $247.56 and above support at $243.19, with improving bearish momentum on the 4h timeframe. The ex-dividend date has passed, which historically creates short-term pressure, and the sector/rates environment is confirming the move. The position is 56.9% toward the $240 target, with no signs of invalidation.
▼ Click to expandWhile the position is progressing, an exit could be justified if ABBV breaks and confirms above $247.56 resistance, signaling a potential reversal. Additionally, if the broader market regime shifts decisively bullish or Healthcare sector strength accelerates, the risk/reward profile could deteriorate.
▼ Click to expandRun Summary
Intraday discovery triggered reanalysis on ABBV. Verdict: HOLD (0/3 EXIT). Conviction: 93.